Specializes in Medical and general practice now LTC.
The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it.
The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection.
The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.
The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.
And here is yet one more reason for me to social distance, mask up, etc., now. If I have to get COVID, I want to get it later, when we know more and have better treatments.
I've considering raising llamas for the antibodies but there's no room for them on my front porch. Scared they might eat my veggies. I think I'll wait for this one instead!
Silverdragon102, BSN
1 Article; 39,477 Posts
The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it.
The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection.
The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.
The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.
Coronavirus: Protein treatment trial 'a breakthrough'
Interesting read